

Jorge Matias-Guiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1515365/publications.pdf>

Version: 2024-02-01

121
papers

2,642
citations

172457

29
h-index

265206

42
g-index

122
all docs

122
docs citations

122
times ranked

3954
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and Verbal Fluency in Alzheimer's Disease and Frontotemporal Dementia: Clinical and Metabolic Correlates. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 947-962.	1.8	10
2	Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 31.	3.0	17
3	The Five-Point Test: Normative data for middle-aged and elderly Spaniards. <i>Applied Neuropsychology Adult</i> , 2022, 29, 1323-1331.	1.2	2
4	Identification of the main components of spontaneous speech in primary progressive aphasia and their neural underpinnings using multimodal MRI and FDG-PET imaging. <i>Cortex</i> , 2022, 146, 141-160.	2.4	9
5	Diagnosis of Alzheimer's disease and behavioural variant frontotemporal dementia with machine learning-aided neuropsychological assessment using feature engineering and genetic algorithms. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	16
6	Examining Association of Personality Characteristics and Neuropsychiatric Symptoms in Post-COVID Syndrome. <i>Brain Sciences</i> , 2022, 12, 265.	2.3	6
7	The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination. <i>Life</i> , 2022, 12, 474.	2.4	6
8	Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach. <i>Frontiers in Neurology</i> , 2022, 13, 838227.	2.4	1
9	Cognitive dysfunction associated with COVID-19: A comprehensive neuropsychological study. <i>Journal of Psychiatric Research</i> , 2022, 150, 40-46.	3.1	76
10	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103805.	2.0	2
11	Persistent olfactory dysfunction after COVID-19 is associated with reduced perfusion in the frontal lobe. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 194-198.	2.1	26
12	Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders. <i>Biomedicines</i> , 2022, 10, 1105.	3.2	13
13	Long-term directional deep brain stimulation: Monopolar review vs. local field potential guided programming. <i>Brain Stimulation</i> , 2022, 15, 727-736.	1.6	11
14	Validation of two new scales for the assessment of fatigue in Multiple Sclerosis: F-2-MS and FACIT-F. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103826.	2.0	4
15	Neuropsychological Predictors of Fatigue in Post-COVID Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 3886.	2.4	7
16	GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer's disease and frontotemporal dementia using genetic algorithms. <i>Medical and Biological Engineering and Computing</i> , 2022, 60, 2737-2756.	2.8	12
17	Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimer's Disease and Multiple Sclerosis. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 711-722.	0.5	5
18	Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. <i>Journal of Medical Virology</i> , 2021, 93, 546-549.	5.0	32

#	ARTICLE	IF	CITATIONS
19	<i>ACE2, TMPRSS2</i>, and Furin variants and SARSâ€CoVâ€2 infection in Madrid, Spain. <i>Journal of Medical Virology</i> , 2021, 93, 863-869.	5.0	72
20	Biocompatibility of ferulic/succinic acid-grafted chitosan hydrogels for implantation after brain injury: A preliminary study. <i>Materials Science and Engineering C</i> , 2021, 121, 111806.	7.3	7
21	Editorial: The Use of Biomaterials With Stem and Precursor Cells in Diseases of the Central Nervous System; A Step to Clinical Trials. <i>Frontiers in Neurology</i> , 2021, 12, 654890.	2.4	3
22	Whole-Exome Sequencing and C9orf72 Analysis in Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 985-990.	2.6	3
23	Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5192.	4.1	4
24	Underpinnings of verbal fluency in Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103056.	2.0	1
25	Personalized Repetitive Transcranial Magnetic Stimulation for Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 151-167.	2.6	17
26	Spanish Version of the Mini-Linguistic State Examination for the Diagnosis of Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 771-778.	2.6	6
27	Application of Machine Learning to Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. <i>Brain Sciences</i> , 2021, 11, 1262.	2.3	8
28	A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9553.	4.1	17
29	Intranasal Administration of Undifferentiated Oligodendrocyte Lineage Cells as a Potential Approach to Deliver Oligodendrocyte Precursor Cells into Brain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10738.	4.1	6
30	â€œBrain Fogâ€ by COVID-19 or Alzheimerâ€™s Disease? A Case Report. <i>Frontiers in Psychology</i> , 2021, 12, 7240221		19
31	Genetic Algorithms for Optimized Diagnosis of Alzheimerâ€™s Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 708932.	3.4	4
32	Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101926.	2.0	16
33	Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. <i>Brain and Behavior</i> , 2020, 10, e01498.	2.2	40
34	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. <i>Frontiers in Immunology</i> , 2020, 11, 2163.	4.8	27
35	Death Rate Due to COVID-19 in Alzheimerâ€™s Disease and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 537-541.	2.6	41
36	Spectrum of Headaches Associated With SARSâ€CoVâ€2 Infection: Study of Healthcare Professionals. <i>Headache</i> , 2020, 60, 1697-1704.	3.9	57

#	ARTICLE	IF	CITATIONS
37	Reading prosody in the non-fluent and logopenic variants of primary progressive aphasia. <i>Cortex</i> , 2020, 132, 63-78.	2.4	12
38	Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 1178-1184.	3.9	4
39	Non-Convulsive Status Epilepticus in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 985-991.	2.6	1
40	Validation of the Spanish version of the Mini-Linguistic State Examination for the diagnosis of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2020, 16, e042817.	0.8	0
41	Metabolic correlates of neuropsychological assessment in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e044097.	0.8	0
42	Personalized repetitive transcranial magnetic stimulation for non-fluent and semantic variants of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2020, 16, e047658.	0.8	0
43	Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 389.	4.1	107
44	Is the brain a reservoir organ for SARS-CoV2?. <i>Journal of Medical Virology</i> , 2020, 92, 2354-2355.	5.0	28
45	Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task. <i>Frontiers in Neurology</i> , 2020, 11, 309.	2.4	5
46	Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102185.	2.0	118
47	Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVID-19 Pandemic?. <i>Headache</i> , 2020, 60, 1448-1449.	3.9	4
48	SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases. <i>Movement Disorders</i> , 2020, 35, 1104-1105.	3.9	16
49	An Online Observational Study of Patients With Olfactory and Gustatory Alterations Secondary to SARS-CoV-2 Infection. <i>Frontiers in Public Health</i> , 2020, 8, 243.	2.7	27
50	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102297.	2.0	25
51	Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 638.	2.4	11
52	Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. <i>Neurourology and Urodynamics</i> , 2020, 39, 762-770.	1.5	13
53	Amyloid β -Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damage. <i>Annals of Neurology</i> , 2020, 87, 988-988.	5.3	2
54	Validation of the Neuronorma battery for neuropsychological assessment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102070.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 629183.	2.4	17
56	Infection Mechanism of SARS-COV-2 and Its Implication on the Nervous System. <i>Frontiers in Immunology</i> , 2020, 11, 621735.	4.8	59
57	Inhibition impairment in frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease: clinical assessment and metabolic correlates. <i>Brain Imaging and Behavior</i> , 2019, 13, 651-659.	2.1	26
58	Differences in age of diagnosis in familial multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 91.	2.0	1
59	Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 773-782.	2.6	10
60	Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's Disease: Clinical and FDG-PET Correlation. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1263-1269.	2.6	15
61	Repetitive transcranial magnetic stimulation in a case of atypical parkinsonism. <i>Brain Stimulation</i> , 2019, 12, 1343-1344.	1.6	0
62	Machine learning in the clinical and language characterisation of primary progressive aphasia variants. <i>Cortex</i> , 2019, 119, 312-323.	2.4	31
63	Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 302.	2.8	16
64	Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole-exome next generation sequencing. <i>Brain and Behavior</i> , 2019, 9, e01272.	2.2	23
65	What is the meaning of PASAT rejection in multiple sclerosis?. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 559-562.	2.1	9
66	Clinical or neuroimaging profiles in the assessment of genetic variants associated with neurodegenerative diseases. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 419-421.	3.9	3
67	Biohybrids of scaffolding hyaluronic acid biomaterials plus adipose stem cells home local neural stem and endothelial cells: Implications for reconstruction of brain lesions after stroke. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2019, 107, 1598-1606.	3.4	17
68	Familial multiple sclerosis and association with other autoimmune diseases. <i>Brain and Behavior</i> , 2018, 8, e00899.	2.2	11
69	Vitamina D y remielinización en la esclerosis múltiple. <i>Neurología</i> , 2018, 33, 177-186.	0.7	26
70	Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 141-150.	2.7	33
71	Conversion between Addenbrooke's Cognitive Examination III and Mini-Mental State Examination. <i>International Psychogeriatrics</i> , 2018, 30, 1227-1233.	1.0	17
72	Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry. <i>Frontiers in Neurology</i> , 2018, 9, 920.	2.4	31

#	ARTICLE	IF	CITATIONS
73	Structural MRI correlates of PASAT performance in multiple sclerosis. <i>BMC Neurology</i> , 2018, 18, 214.	1.8	20
74	Evaluation of the Safety and Efficacy of the Therapeutic Potential of Adipose-Derived Stem Cells Injected in the Cerebral Ischemic Penumbra. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2453-2465.	1.6	8
75	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 85.	6.2	69
76	Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 230.	3.4	22
77	Novedades en esclerosis múltiple: la remielinización como objetivo terapéutico. <i>Medicina Clínica</i> , 2017, 148, 377-380.	0.6	7
78	Neural Basis of Cognitive Assessment in Alzheimer Disease, Amnesic Mild Cognitive Impairment, and Subjective Memory Complaints. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 730-740.	1.2	24
79	Amyloid PET in pseudotumoral multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 15-17.	2.0	7
80	Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology. <i>Prion</i> , 2017, 11, 205-213.	1.8	16
81	News in multiple sclerosis: Remyelination as a therapeutic target. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 377-380.	0.2	5
82	Reading difficulties in primary progressive aphasia in a regular language-speaking cohort of patients. <i>Neuropsychologia</i> , 2017, 101, 132-140.	1.6	18
83	FDG-PET/CT or MRI for the Diagnosis of Primary Progressive Aphasia?. <i>American Journal of Neuroradiology</i> , 2017, 38, E63-E63.	2.4	8
84	Comparative Diagnostic Accuracy of the ACE-III, MIS, MMSE, MoCA, and RUDAS for Screening of Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 43, 237-246.	1.5	80
85	Teaching Neuro Images : Adult-onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome). <i>Neurology</i> , 2017, 88, e113-e114.	1.1	3
86	Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1251-1264.	2.6	38
87	Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 733-742.	2.6	31
88	Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests. <i>International Psychogeriatrics</i> , 2017, 29, 105-113.	1.0	67
89	Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 71-76.	2.0	8
90	Comparison between FCSRT and LASSI-L to Detect Early Stage Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 103-111.	2.6	27

#	ARTICLE	IF	CITATIONS
91	Alexander Disease Mutations Produce Cells with Coexpression of Glial Fibrillary Acidic Protein and NG2 in Neurosphere Cultures and Inhibit Differentiation into Mature Oligodendrocytes. <i>Frontiers in Neurology</i> , 2017, 8, 255.	2.4	19
92	Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. <i>Frontiers in Neurology</i> , 2017, 8, 643.	2.4	40
93	Amyotrophic lateral sclerosis modifies progenitor neural proliferation in adult classic neurogenic brain niches. <i>BMC Neurology</i> , 2017, 17, 173.	1.8	46
94	Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. <i>Frontiers in Neurology</i> , 2016, 7, 53.	2.4	44
95	Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 195.	2.4	25
96	Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 166-166.	5.3	7
97	Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 243-250.	1.5	35
98	ITH33/IQM9.21 provides neuroprotection in a novel ALS model based on TDP-43 and Na ⁺ /Ca ²⁺ overload induced by VTD. <i>Neuroscience Letters</i> , 2016, 633, 28-32.	2.1	2
99	Olanzapine: Pharmacodynamics of the Oral Bace Inhibitor JNJ54861911 in Early Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P199.	0.8	4
100	Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population. <i>European Neurology</i> , 2016, 76, 202-209.	1.4	9
101	Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2050-2060.	6.4	48
102	The Hayling Test: Development and Normalization of the Spanish Version. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 411-419.	0.5	25
103	Validation of the Lille's Apathy Rating Scale in Very Mild to Moderate Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 517-527.	1.2	15
104	Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. <i>BMC Neurology</i> , 2015, 15, 243.	1.8	58
105	Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study. <i>Scientific World Journal</i> , The, 2015, 2015, 1-8.	2.1	28
106	Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 916-927.	6.4	35
107	Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. <i>Journal of Neurology</i> , 2015, 262, 1463-1472.	3.6	39
108	Clinical course of primary progressive aphasia: clinical and FDG-PET patterns. <i>Journal of Neurology</i> , 2015, 262, 570-577.	3.6	41

#	ARTICLE	IF	CITATIONS
109	Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	9
110	Validation of a Spanish Version of the Lille Apathy Rating Scale for Parkinson's Disease. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	18
111	Factors Associated with the Differences in Migraine Prevalence Rates between Spanish Regions. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	5
112	Stroke etiology determines effectiveness of retrievable stents: Table 1. Journal of NeuroInterventional Surgery, 2014, 6, e11-e11.	3.3	40
113	Primary progressive aphasia with occipital impairment. Journal of the Neurological Sciences, 2014, 347, 387-388.	0.6	3
114	Evaluation of the New Consensus Criteria for the Diagnosis of Primary Progressive Aphasia Using Fluorodeoxyglucose Positron Emission Tomography. Dementia and Geriatric Cognitive Disorders, 2014, 38, 147-152.	1.5	31
115	The Adult Macaque Spinal Cord Central Canal Zone Contains Proliferative Cells And Closely Resembles The Human. Journal of Comparative Neurology, 2014, 522, 1800-1817.	1.6	36
116	The Neuroprotection Exerted by Memantine, Minocycline and Lithium, against Neurotoxicity of CSF from Patients with Amyotrophic Lateral Sclerosis, Is Antagonized by Riluzole. Neurodegenerative Diseases, 2014, 13, 171-179.	1.4	24
117	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. Patient, 2012, 5, 147-162.	2.7	9
118	Subventricular zone in motor neuron disease with frontotemporal dementia. Neuroscience Letters, 2011, 499, 9-13.	2.1	14
119	CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: Protection by resveratrol but not riluzole. Brain Research, 2011, 1423, 77-86.	2.2	50
120	One-year prevalence of migraine in Spain: A nationwide population-based survey. Cephalalgia, 2011, 31, 463-470.	3.9	69
121	Paroxysmal head pain with backward radiation: will epicrania fugax go in the opposite direction?. Journal of Headache and Pain, 2010, 11, 75-78.	6.0	21